The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy

免疫球蛋白A肾病中针对β2-Spectrin和CBX3的IgA抗体的流行率和特征

阅读:1

Abstract

INTRODUCTION: In IgA nephropathy (IgAN), the mechanism of IgA-containing immune complexes deposition in the glomerular mesangium had been unclear. We recently reported the presence of IgA antibodies with specificity for mesangial cells (antimesangium IgA antibodies) in sera from patients with IgAN, and identified β2-spectrin (SPTBN1) and CBX3 as target antigens. However, the role of antimesangium IgA antibodies in human IgAN is unclear. METHODS: We measured serum anti-SPTBN1 and anti-CBX3 IgA levels in patients with IgAN (n = 119) and other kidney diseases (disease control [DC], n = 51) using 2 independent cohorts, 1 from Japan and 1 from the UK. The study also assessed the surface expression of the autoantigens on human mesangial cells and the pattern of O-glycosylation of serum anti-SPTBN1 and anti-CBX3 IgA antibodies. RESULTS: Overall, 30 and 3 patients with IgAN and DC, respectively, had detectable anti-SPTBN1 IgA antibodies (sensitivity, 25%; specificity, 94%); whereas 48 and 3 patients with IgAN and DC, respectively, had detectable anti-CBX3 IgA antibodies (sensitivity, 40%; specificity, 94%). In total, 62 patients (52%) with IgAN had detectable anti-SPTBN1 and/or anti-CBX3 IgA antibodies. The expression of SPTBN1 and CBX3 on the surface of human mesangial cells was confirmed by immunofluorescence (IF) microscopy. Serum anti-SPTBN1 and anti-CBX3 IgA antibodies from patients with IgAN were recognized by an antigalactose-deficient IgA1 antibody (KM55) by Western blotting. CONCLUSION: We show that anti-SPTBN1 and anti-CBX3 IgA antibodies are detected with high specificity in patients with IgAN from Japan and the UK, and are enriched for IgA1 with poorly galactosylated O-glycoforms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。